<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780715</url>
  </required_header>
  <id_info>
    <org_study_id>2008DM05</org_study_id>
    <secondary_id>EudraCT 2008-004790-18</secondary_id>
    <nct_id>NCT00780715</nct_id>
  </id_info>
  <brief_title>Response To Oral Agents in Diabetes (ROAD)- Pilot Study</brief_title>
  <acronym>ROAD</acronym>
  <official_title>Response To Oral Agents in Diabetes (ROAD)- Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal is to fund a pilot study to assess feasibility and refine methodology for an
      intended large Scotland wide study on Response to Oral Agents in Diabetes (ROAD). The study
      will collect cohorts of patients who have carefully controlled standardised dose titration
      and monitoring with an assessment of drug response and side effects over a 6 month period.
      The primary aim will be to use these cohorts to investigate phenotypic and genotypic
      (pharmacogenetic) determinants of response.

      Drug na√Øve patients will be treated with Metformin. Patients who have failed on Metformin or
      are intolerant of Metformin will be randomised to gliclazide, pioglitazone or sitagliptin.
      With the ability to capture patient data beyond 6 months via data linkage we will monitor
      time to treatment failure and therefore compare which of the 3 oral agents is the best
      therapy to use after Metformin in a cost efficient and &quot;real world&quot; RCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Response to Oral Agents in Diabetes (ROAD) study aims to address the limitations of
      observational data by creating a prospective study of incident users of oral agents. For the
      first six months the research team will ensure a protocol driven dose titration, standardised
      monitoring of adherence, response and side effects and standardised deviations from therapy.
      Thereafter patients will receive 6 monthly monitoring and further protocol led dose titration
      by the GP. Biochemistry, prescribing data, morbidity and mortality data will be captured for
      up to 10 years from drug initiation. The ROAD study will provide a highly powered prospective
      cohort to investigate phenotypic and genotypic determinants of response in its own right.
      However, this cohort will be used synergistically with ongoing observational pharmacogenetics
      studies, allowing for crucial replication of 'positive' signals. Furthermore, by
      randomisation at drug initiation, long term community follow up will allow a comparison of
      time to treatment failure in patients treated with gliclazide, pioglitazone and sitagliptin
      in a much more cost effective and 'real-world' setting than traditional prospective
      randomised trials This pilot study is to assess the feasibility of the larger complex
      intervention. The primary outcome of the pilot is HbA1c change. Other measures regarding
      recruitment and dose titration will be assessed. With knowledge from this pilot, an
      application will be made for a large region or Scotland wide study to collect 2000 patients
      incident to oral diabetes treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Change</measure>
    <time_frame>6 months</time_frame>
    <description>Units are absolute difference in %HbA1c (HbA1c being the percentage of glycated Haemoglobin, reflecting glucose exposure over the last 3 months)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Gliclazide MR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide MR</intervention_name>
    <description>30mg daily increased to 60mg if HbA1c &gt; 7% at 3 months</description>
    <arm_group_label>Gliclazide MR</arm_group_label>
    <other_name>Diamicron MR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100mg daily for 6 months</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 30mg daily , increased to 45mg daily if HbA1c &gt;7% at 3 months. 6 months duration</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cohort 1 - metformin treatment

               -  Type 2 diabetes diagnosed more than 6 weeks prior to visit 1

               -  GP considers adequate diet and lifestyle advice given

               -  Age &gt;35 and &lt; 80

               -  Age of diabetes diagnosis &gt;35

               -  White European

               -  HbA1c &gt;7% &amp; &lt;=9%

               -  eGFR&gt;=50 ml/min

               -  ALT &lt;= 2.5*ULN

               -  Contactable by telephone

          -  Cohort 2 - 2nd line treatment

               -  Type 2 diabetes

               -  Treated with metformin for more than 3 months; or metformin intolerant

               -  Age &gt;35 and &lt; 80

               -  Age of diabetes diagnosis &gt;35

               -  White European

               -  HbA1c &gt;7% &amp; &lt;=9%

               -  eGFR&gt;=50 ml/min

               -  ALT &lt;= 2.5*ULN

               -  No previous history of heart failure; No patients with documented evidence of
                  left ventricular systolic dysfunction OR with symptoms and signs consistent with
                  a clinical diagnosis of heart failure

               -  No treatment with Gemfibrozil or Rifampicin (CYP2C8 inhibitor or inducer
                  respectively); or with Miconazole or phenylbutazone (increased hypoglycemic
                  effect of gliclazide).

               -  No diagnosis of osteoporosis

               -  Contactable by telephone

        Exclusion Criteria:

          -  Cohort 1

               -  Type 1 diabetes

               -  HbA1c &gt;9% or &lt;=7%

               -  eGFR&lt;50 ml/min

               -  ALT &gt; 2.5*ULN

               -  Alcohol consumption in excess of 50 units per week

               -  Pregnancy, lactation or a female planning to conceive within the study period

               -  Any other significant medical reason for exclusion as determined by the
                  investigator

          -  Cohort 2

               -  Type 1 diabetes

               -  HbA1c &gt;9% or &lt;=7%

               -  eGFR&lt; 50 ml/min

               -  ALT &gt; 2.5*ULN

               -  Previous history of heart failure OR documented evidence of left ventricular
                  systolic dysfunction OR symptoms and signs consistent with a clinical diagnosis
                  of heart failure

               -  Ongoing treatment with Gemfibrozil or Rifampicin (CYP2C8 inhibitor or inducer
                  respectively); or with Miconazole or phenylbutazone (increased hypoglycemic
                  effect of gliclazide).

               -  Previous diagnosis of osteoporosis

               -  Pregnancy, lactation or a female planning to conceive within the study period

               -  Any other significant medical reason for exclusion as determined by the
                  investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>36 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewan R Pearson</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ninewells Hospital &amp; Medical School</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2008</study_first_submitted>
  <study_first_submitted_qc>October 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <results_first_submitted>May 24, 2017</results_first_submitted>
  <results_first_submitted_qc>October 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2017</results_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Ewan Pearson</investigator_full_name>
    <investigator_title>Professor of Diabetic Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes therapies</keyword>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gliclazide MR</title>
          <description>Gliclazide MR: 30mg daily increased to 60mg if HbA1c &gt; 7% at 3 months</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin</title>
          <description>Sitagliptin: Sitagliptin 100mg daily for 6 months</description>
        </group>
        <group group_id="P3">
          <title>Pioglitazone</title>
          <description>Pioglitazone: Pioglitazone 30mg daily , increased to 45mg daily if HbA1c &gt;7% at 3 months. 6 months duration</description>
        </group>
        <group group_id="P4">
          <title>Metformin</title>
          <description>Metformin: Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gliclazide MR</title>
          <description>Gliclazide MR: 30mg daily increased to 60mg if HbA1c &gt; 7% at 3 months</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin</title>
          <description>Sitagliptin: Sitagliptin 100mg daily for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Pioglitazone</title>
          <description>Pioglitazone: Pioglitazone 30mg daily , increased to 45mg daily if HbA1c &gt;7% at 3 months. 6 months duration</description>
        </group>
        <group group_id="B4">
          <title>Metformin</title>
          <description>Metformin: Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="4.6"/>
                    <measurement group_id="B2" value="61.5" spread="9.9"/>
                    <measurement group_id="B3" value="61.3" spread="11.8"/>
                    <measurement group_id="B4" value="59.6" spread="8.8"/>
                    <measurement group_id="B5" value="60.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change</title>
        <description>Units are absolute difference in %HbA1c (HbA1c being the percentage of glycated Haemoglobin, reflecting glucose exposure over the last 3 months)</description>
        <time_frame>6 months</time_frame>
        <population>Modified Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Gliclazide MR</title>
            <description>Gliclazide MR: 30mg daily increased to 60mg if HbA1c &gt; 7% at 3 months</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Sitagliptin 100mg daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone</title>
            <description>Pioglitazone: Pioglitazone 30mg daily , increased to 45mg daily if HbA1c &gt;7% at 3 months. 6 months duration</description>
          </group>
          <group group_id="O4">
            <title>Metformin</title>
            <description>Metformin: Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change</title>
          <description>Units are absolute difference in %HbA1c (HbA1c being the percentage of glycated Haemoglobin, reflecting glucose exposure over the last 3 months)</description>
          <population>Modified Intention to treat</population>
          <units>absolute change in %HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.72"/>
                    <measurement group_id="O2" value="-0.58" spread="0.63"/>
                    <measurement group_id="O3" value="-1.04" spread="0.71"/>
                    <measurement group_id="O4" value="-1.59" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gliclazide MR</title>
          <description>Gliclazide MR: 30mg daily increased to 60mg if HbA1c &gt; 7% at 3 months</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin</title>
          <description>Sitagliptin: Sitagliptin 100mg daily for 6 months</description>
        </group>
        <group group_id="E3">
          <title>Pioglitazone</title>
          <description>Pioglitazone: Pioglitazone 30mg daily , increased to 45mg daily if HbA1c &gt;7% at 3 months. 6 months duration</description>
        </group>
        <group group_id="E4">
          <title>Metformin</title>
          <description>Metformin: Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Note that this study was a pilot study and was not designed or powered to show significance of differences in outcomes between groups. Primary aim was to demonstrate efficacy of novel route of recruitment from primary care.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Ewan Pearson</name_or_title>
      <organization>University of Dundee</organization>
      <phone>+44 (0) 1382 383387</phone>
      <email>e.z.pearson@dundee.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

